Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Learn more about whether Nurix Therapeutics, Inc. or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Lawmakers split after ...

Former Google CEO Eric Schmidt expressed astonishment at AI's rapid progress, particularly its ability to autonomously ...

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...

November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...

Few would place Recursion Pharmaceuticals (NASDAQ: RXRX), a little-known biotech company, in the same league as these tech giants when it comes to AI stocks. But could the small drugmaker actually ...

With the popularity of AI coding tools rising among some software developers, their adoption has begun to touch every aspect of the process, including the improvement of AI coding tools themselves.